In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Raphael Landovitz from the UCLA Medical School about the latest information on HIV prevention via Preexposure Prophylaxis, or PrEP. They discuss the history of PrEP and early efficacy and then move into a discussion of the evolution of PrEP from episodic dosing to longer-acting therapies. The episode also highlights recent research and how that may impact the future of PrEP dosing.
0:00 - Introduction
1:59 - History of Preexposure Prophylaxis, or PrEP
5:39 - Why initial PrEP regimens were not 100% effective
12:01 - Discussion of episodic PrEP and 2-1-1 regimens
16:22 - How longer-acting therapy has been shown to be superior to episodic dosing
20:29 - LEVI syndrome - what is it?
25:05 - What the future holds for PrEP
29:18 - Closing Remarks
10 сен 2024
